Synthaverse SA
WSE:SVE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.5), the stock would be worth zł4.74 (43% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1 | zł3.3 |
0%
|
| 3-Year Average | 1.5 | zł4.74 |
+43%
|
| 5-Year Average | 2.3 | zł7.38 |
+124%
|
| Industry Average | 88.7 | zł289.46 |
+8 671%
|
| Country Average | 0.9 | zł2.87 |
-13%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
S
|
Synthaverse SA
WSE:SVE
|
233.5m PLN | 1 | -38.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 4.5 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 3.6 | 22.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 3.7 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 7.3 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 5.6 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 1.5 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 0.9 |
| 70th Percentile | 1.9 |
| Max | 116.3 |
Other Multiples
Synthaverse SA
Glance View
Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.
